Literature DB >> 16423989

Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma.

Michael I Koukourakis1, Alexandra Giatromanolaki, Adrian L Harris, Efthimios Sivridis.   

Abstract

Understanding tumor metabolism is important for the development of anticancer therapies. Immunohistochemical evaluation of colorectal adenocarcinomas showed that cancer cells share common enzyme/transporter activities suggestive of an anaerobic metabolism [high lactate dehydrogenase 5 (LDH5)/hypoxia-inducible factor alphas (HIFalphas)] with high ability for glucose absorption and lactate extrusion [high glucose transporter 1 (GLUT1)/monocarboxylate transporter (MCT1)]. The tumor-associated fibroblasts expressed proteins involved in lactate absorption (high MCT1/MCT2), lactate oxidation (high LDH1 and low HIFalphas/LDH5), and reduced glucose absorption (low GLUT1). The expression profile of the tumor-associated endothelium indicated aerobic metabolism (high LDH1 and low HIFalphas/LDH5), high glucose absorption (high GLUT1), and resistance to lactate intake (lack of MCT1). It is suggested that the newly formed stroma and vasculature express complementary metabolic pathways, buffering and recycling products of anaerobic metabolism to sustain cancer cell survival. Tumors survive and grow because they are capable of organizing the regional fibroblasts and endothelial cells into a harmoniously collaborating metabolic domain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423989     DOI: 10.1158/0008-5472.CAN-05-3260

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  172 in total

1.  Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma.

Authors:  Changjun He; Xue-Pu Sun; Haiquan Qiao; Xian Jiang; Dongdong Wang; Xiangguo Jin; Xuesong Dong; Jizhou Wang; Hongchi Jiang; Xueying Sun
Journal:  Cancer Sci       Date:  2012-01-13       Impact factor: 6.716

Review 2.  Role of monocarboxylate transporters in human cancers: state of the art.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; João Azevedo-Silva; Margarida Casal; Fernando C Schmitt; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

3.  Modeling community-wide molecular networks of multicellular systems.

Authors:  Kakajan Komurov
Journal:  Bioinformatics       Date:  2011-12-30       Impact factor: 6.937

Review 4.  Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.

Authors:  Wan Zhang; Peng Huang
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

5.  Changing the energy of an immune response.

Authors:  Meghan M Delmastro-Greenwood; Jon D Piganelli
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

6.  HIF-1α and GLUT-1 Expression in Atypical Endometrial Hyperplasia, Type I and II Endometrial Carcinoma: A Potential Role in Pathogenesis.

Authors:  Dalia Rifaat Al-Sharaky; Asmaa Gaber Abdou; Moshira Mohammed Abdel Wahed; Hend Abdou Kassem
Journal:  J Clin Diagn Res       Date:  2016-05-01

7.  Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells.

Authors:  Mark G Slomiany; G Daniel Grass; Angela D Robertson; Xiao Y Yang; Bernard L Maria; Craig Beeson; Bryan P Toole
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma.

Authors:  Xiao-Hong Wu; Su-Ping Chen; Jian-Ying Mao; Xue-Xian Ji; Hong-Tian Yao; Shui-Hong Zhou
Journal:  Oncol Lett       Date:  2012-09-26       Impact factor: 2.967

9.  Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review).

Authors:  Jie Zheng
Journal:  Oncol Lett       Date:  2012-09-20       Impact factor: 2.967

10.  Fusion between cancer cells and myofibroblasts is involved in osteosarcoma.

Authors:  Ling Yu; Weichun Guo; Shenghao Zhao; Fuan Wang; Yong Xu
Journal:  Oncol Lett       Date:  2011-07-14       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.